偏头痛预防治疗的进展
偏头痛给患者和社会带来沉重负担,预防性治疗长期使用不足。大型随机试验证实靶向降钙素基因相关肽(CGRP)的药物耐受性和有效性良好,偏头痛特异性预防药较长治疗周期的依从性优于非特异性治疗,可改善疾病控制并惠及既往非特异性预防药无效者。
要点
- 偏头痛预防治疗使用不足,患者过度依赖急性治疗可能加重病情。
- 大型随机试验证实CGRP靶向药物耐受性和有效性良好。
- 偏头痛特异性预防药依从性优于非特异性治疗,可改善疾病控制。
核心结论
- 偏头痛特异性预防药(如CGRP靶向治疗)可优化偏头痛管理,改善疾病控制和生活质量。
研究设计与样本
- 大型随机试验确立了CGRP靶向药物的耐受性和有效性。
主要发现
- 偏头痛特异性预防药较长治疗周期的依从性高于非特异性治疗。
- CGRP靶向药物使既往非特异性预防药无效的偏头痛患者受益。
临床怎么用
- 应增加偏头痛特异性预防药的使用,减少对急性治疗的过度依赖。
- 对非特异性预防药无效者可选CGRP靶向治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Migraine imposes a heavy burden on patients and societies. Preventive treatments aimed at reducing the occurrence of migraine attacks and their intensity have been largely underused, leaving a multitude of people with migraine to rely exclusively on acute treatments, which, when used in excess, might even worsen the clinical situation. Large, randomised trials have established the tolerability and efficacy of calcitonin gene-related peptide (CGRP)-targeting drugs, a new class of migraine-specific treatment. The increased adherence to longer treatment cycles with migraine-specific preventive drugs, such as CGRP-targeting therapies, compared with non-migraine specific treatments has the potential to improve control of the disease. These migraine-specific drugs also provide benefits to individuals with migraine who previously did not benefit from non-specific migraine preventive medications. Increased reliance on preventive treatment with migraine-specific options is progressively optimising the management of migraine for mounting numbers of patients disabled by the disease, thereby improving disease control and their quality of life.
引用
- Martinelli D, De Icco R, Al-Khazali HM, et al. Advances in migraine prevention. Lancet Neurol. 2026. PMID: 41722594. doi:10.1016/S1474-4422(25)00477-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。